Emergent BioSolutions Inc (EBS)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

400 PROFESSIONAL DR, SUITE 400 GAITHERSBURG, MD 20879

Emergent BioSolutions Inc. develops, manufactures, and commercializes immunobiotics such as vaccines and immune globulins that assist the body's immune system. The company's biodefense segment develops, manufactures, and commercializes drugs such as BioThrax, a vaccine for the prevention of anthrax, for use against biological agents. Other products in preclinical development include drugs for the treatment of patients after they are exposed to anthrax and botulinum toxin. Emergent's commercial segment develops products for use against infectious diseases. These include a single-dose typhoid vaccine in phase II clinical development; a hepatitis B vaccine in phase II clinical development, and a group B streptococcus vaccine for women of childbearing age for protection of the fetus and newborn babies, which is in phase I clinical trials. Emergent is also developing chlamydia and meningitis B vaccines. Emergent primarily works for the U.S. Defense and Health & Human Services departments. It has collaboration agreements with the British Health Protection Agency for the development of a human botulinum immune globulin candidate and with Sanofi Pasteur for the development of meningitis B vaccine candidate.

Data as of 2020-05-24
Market Cap4.435 Billion Shares Outstanding52.428 Million Avg 30-day Volume534.674 Thousand
P/E Ratio65.1 Dividend Yield EPS1.3
Price/Sales4.003 Price cash flow ratio31.6 Price free cash flow ratio86.4
Book Value20.5 Price to Tangible Book62.2 Alpha0.02
Short Interest Ratio4.57 % Short Interest to Float4.4 R-squared0.234712
BETA1.36453 52-week High/Low90.0 / 39.11 Stddev0.119611
View SEC Filings from EBS instead.

View recent insider trading info

Funds Holding EBS (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding EBS BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

382.2 Thousand total shares from 31 transactions

Exercise Derivative Conversion (M)

59.2 Thousand total shares from 6 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

HAUER JEROME M

  • Director
10,188 2020-05-26 3

ZOON KATHRYN C

  • Director
13,489 2020-05-26 7

MULLIGAN SEAMUS

  • Director
1,152,788 2020-05-26 0

RICHARD RONALD

  • Director
10,841 2020-05-21 5

HARSANYI ZSOLT

  • Director
31,188 2020-05-21 5

SULLIVAN LOUIS W

  • Director
63,287 2020-05-21 2

BAILEY SUE

  • Director
42,582 2020-05-21 3

JOULWAN GEORGE A

  • Director
32,771 2020-05-21 2

KRAMER ROBERT PRESIDENT AND CEO

  • Officer
  • Director
142,203 2020-05-08 2

STREI KATHERINE EVP, CHIEF HR OFFICER

  • Officer
28,009 2020-05-08 2

LINDAHL RICHARD S EVP, CHIEF FINANCIAL OFFICER

  • Officer
31,806 2020-05-08 2

ELSEY R DON CFO, TREASURER & SECRETARY

  • Officer
0 2020-04-30 0

EL-HIBRI FUAD CHAIRMAN

  • Officer
  • Director
  • 10% Owner
7,097,928 2020-04-29 13

HAVEY ADAM EVP, BUSINESS OPERATIONS

  • Officer
34,256 2020-04-17 3

KIRK SEAN EVP, MANUFACTURING & TECH OPS

  • Officer
12,571 2020-04-06 3

SARAN ATUL EVP, CORP DEV, GC & SECRETARY

  • Officer
40,799 2020-02-25 2

WHITE MARVIN L PRESIDENT AND CEO

  • Officer
  • Director
0 2020-02-18 0

ABDUN-NABI DANIEL BOARD OF DIRECTORS

109,351 2019-06-25 0

NIEDERHUBER JOHN BOARD OF DIRECTORS

0 2019-06-01 0

EMERGENT BIOSOLUTIONS INC.

  • SEAN KIRK, EVP, MANUFACTURING
13,604 2019-05-23 0

INTERVAC, L.L.C.

  • 10% Owner
0 2016-08-01 0

LABINGER BARRY EVP, BIOSCIENCES DIV.

  • Officer
25,182 2015-11-13 0

CHATFIELD STEVEN EVP, BIOSCIENCES

  • Officer
28,000 2013-03-14 0

ALLBAUGH JOE M

  • Director
523,713 2011-07-01 0

KEESE KYLE EVP, BIOSCIENCES DIVISION

  • Officer
18,759 2011-03-15 0

LOCKHART STEPHEN SVP PRODUCT DEVELOPMENT

  • Officer
6,980 2010-11-11 0

BIOPHARM, L.L.C.

  • 10% Owner
No longer subject to file 2010-05-27 0

ESPOSITO DENISE CLO

  • Officer
0 2009-03-10 0

BIOLOGIKA, L.L.C.

  • MEMBER 13(D) GROUP OWNING >10%
1,399,764 2008-06-04 0

MICHIGAN BIOLOGIC PRODUCTS, INC.

  • MEMBER 13(D) GROUP OWNING >10%
1,328,018 2008-01-14 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

ZOON KATHRYN C - Director

2020-05-26 S 4,093 $85.10 d 13,489 13,489.00 direct

HAUER JEROME M - Director

2020-05-26 S 4,385 $85.15 d 10,188 10,188.00 direct

ZOON KATHRYN C - Director

2020-05-21 A 2,821 a 17,582 17,582.00 direct

SULLIVAN LOUIS W - Director

2020-05-21 A 2,821 a 63,287 63,287.00 direct

BAILEY SUE - Director

2020-05-21 A 2,821 a 42,582 42,582.00 direct

JOULWAN GEORGE A - Director

2020-05-21 A 2,821 a 32,771 32,771.00 direct

HARSANYI ZSOLT - Director

2020-05-21 A 2,821 a 31,188 31,188.00 direct

RICHARD RONALD - Director

2020-05-21 A 2,821 a 10,841 10,841.00 direct

HAUER JEROME M - Director

2020-05-21 A 2,821 a 14,573 14,573.00 direct

HARSANYI ZSOLT - Director

2020-05-14 M 3,434 d 0 28,367.00 direct

HARSANYI ZSOLT - Director

2020-05-14 M 3,434 $18.64 a 28,367 28,367.00 direct

ZOON KATHRYN C - Director

2020-05-12 S 1,660 $85.21 d 14,761 14,761.00 direct

JOULWAN GEORGE A - Director

2020-05-11 S 2,000 $85.19 d 29,950 29,950.00 direct

HARSANYI ZSOLT - Director

2020-05-11 S 4,940 $81.99 d 24,933 24,933.00 direct

STREI KATHERINE - Officer EVP, CHIEF HR OFFICER

2020-05-08 F 237 $79.25 d 28,009 28,009.00 direct

KRAMER ROBERT - Director - Officer PRESIDENT AND CEO

2020-05-08 F 95 $79.25 d 142,203 142,203.00 direct

LINDAHL RICHARD S - Officer EVP, CHIEF FINANCIAL OFFICER

2020-05-08 F 728 $79.25 d 31,806 31,806.00 direct

RICHARD RONALD - Director

2020-05-05 S 8,375 $80.19 d 8,020 8,020.00 direct

EL-HIBRI FUAD - Director - Officer - > 10% Owner CHAIRMAN

2020-04-30 S 20,000 $74.01 d 1,229,523 7,097,928.00 direct yes

EL-HIBRI FUAD - Director - Officer - > 10% Owner CHAIRMAN

2020-04-29 S 20,000 $74.24 d 1,249,523 7,097,928.00 direct yes

RICHARD RONALD - Director

2020-04-27 M 7,893 $20.08 a 24,288 16,395.00 direct

RICHARD RONALD - Director

2020-04-27 M 7,893 $78.00 d 0 16,395.00 direct yes

RICHARD RONALD - Director

2020-04-27 S 7,893 $78.00 d 16,395 16,395.00 direct

EL-HIBRI FUAD - Director - Officer - > 10% Owner CHAIRMAN

2020-04-23 S 20,000 $68.49 d 1,269,523 7,137,928.00 direct yes

EL-HIBRI FUAD - Director - Officer - > 10% Owner CHAIRMAN

2020-04-22 S 20,000 $66.81 d 1,289,523 7,137,928.00 direct yes

HAVEY ADAM - Officer EVP, BUSINESS OPERATIONS

2020-04-20 S 17,009 d 80,384 34,256.00 direct yes

HAVEY ADAM - Officer EVP, BUSINESS OPERATIONS

2020-04-20 M 17,009 $30.86 a 51,265 34,256.00 direct yes

HAVEY ADAM - Officer EVP, BUSINESS OPERATIONS

2020-04-20 S 17,009 $69.00 d 34,256 34,256.00 direct yes

HAVEY ADAM - Officer EVP, BUSINESS OPERATIONS

2020-04-17 S 20,414 d 97,393 34,256.00 direct yes

HAVEY ADAM - Officer EVP, BUSINESS OPERATIONS

2020-04-17 S 20,414 $65.00 d 34,256 34,256.00 direct yes

HAVEY ADAM - Officer EVP, BUSINESS OPERATIONS

2020-04-17 M 20,414 $26.45 a 54,670 34,256.00 direct yes

EL-HIBRI FUAD - Director - Officer - > 10% Owner CHAIRMAN

2020-04-16 S 20,000 $62.47 d 1,309,523 7,177,928.00 direct yes

EL-HIBRI FUAD - Director - Officer - > 10% Owner CHAIRMAN

2020-04-15 S 12,537 $62.58 d 1,329,523 7,197,928.00 direct yes

EL-HIBRI FUAD - Director - Officer - > 10% Owner CHAIRMAN

2020-04-14 S 6,261 $62.99 d 1,342,060 7,197,928.00 direct yes

EL-HIBRI FUAD - Director - Officer - > 10% Owner CHAIRMAN

2020-04-13 S 17,071 $62.25 d 1,348,321 7,197,928.00 direct yes

EL-HIBRI FUAD - Director - Officer - > 10% Owner CHAIRMAN

2020-04-09 S 23,716 $61.83 d 1,365,392 7,233,797.00 direct yes

EL-HIBRI FUAD - Director - Officer - > 10% Owner CHAIRMAN

2020-04-08 S 13,000 $60.75 d 1,413,470 7,233,797.00 direct yes

EL-HIBRI FUAD - Director - Officer - > 10% Owner CHAIRMAN

2020-04-08 S 24,362 $61.34 d 1,389,108 7,233,797.00 direct yes

EL-HIBRI FUAD - Director - Officer - > 10% Owner CHAIRMAN

2020-04-07 S 14,336 $60.76 d 1,426,470 7,294,875.00 direct yes

KIRK SEAN - Officer EVP, MANUFACTURING & TECH OPS

2020-04-06 S 5,666 $60.00 d 12,571 12,571.00 direct

HAVEY ADAM - Officer EVP, BUSINESS OPERATIONS

2020-04-06 S 3,730 $60.00 d 34,256 34,256.00 direct

KIRK SEAN - Officer EVP, MANUFACTURING & TECH OPS

2020-04-06 S 3,135 $60.00 d 38,805 12,571.00 direct yes

KIRK SEAN - Officer EVP, MANUFACTURING & TECH OPS

2020-04-06 S 3,135 $60.00 d 12,571 12,571.00 direct yes

HAVEY ADAM - Officer EVP, BUSINESS OPERATIONS

2020-04-06 S 4,242 $60.00 d 37,986 34,256.00 direct

KIRK SEAN - Officer EVP, MANUFACTURING & TECH OPS

2020-04-06 S 7,293 $60.00 d 12,571 12,571.00 direct yes

KIRK SEAN - Officer EVP, MANUFACTURING & TECH OPS

2020-04-06 M 3,135 $30.86 a 15,706 12,571.00 direct yes

EL-HIBRI FUAD - Director - Officer - > 10% Owner CHAIRMAN

2020-04-06 S 28,240 $60.50 d 1,440,806 7,294,875.00 direct yes

KIRK SEAN - Officer EVP, MANUFACTURING & TECH OPS

2020-04-06 S 7,293 $60.00 d 31,512 12,571.00 direct yes

KIRK SEAN - Officer EVP, MANUFACTURING & TECH OPS

2020-04-06 M 7,293 $30.63 a 19,864 12,571.00 direct yes

Elevate your investments